ANN ARBOR, Mich., – April 5, 2023 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces today that it is preparing a response to the United States Air Force under the Defense Production Act Investments (DPAI) program. In its efforts to strengthen the U.S. bio-industrial manufacturing capabilities, the U.S. Government is seeking input from industry to identify target areas for governmental investment. 

Under the 2023 National Defense Authorization Act and through executive order, the Secretary of Defense has been authorized to “incentives the expansion of domestic, flexible industrial biomanufacturing capacity for a wide range of materials.” Biosynthetic fibers such as spider silk were specifically identified as a material/technology of interest under this directive. 

Kraig Labs is preparing a detailed response for submission to the U.S. Air Force by its April 19 deadline. While this request for information does not guarantee a subsequent request for proposal or that funding will be available, it does signify the importance that materials, such as spider silk, can play both economically and defensively.   

“We are very pleased to see the renewed support and interest from the Department of Defense (DoD) to strength the U.S. industry supply base for bio-engineering and bio-manufactured materials,” said Company COO Jon Rice. “I believe that Kraig Labs is and will remain a key player in our domestic biomanufacturing capabilities, and we welcome the opportunity to bring the DoD up to date with our progress and the opportunities that lie ahead.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – February 28, 2023 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces today that it has created and seeks to fill two new senior-level genetic engineering positions within its U.S. based research and development team. These new roles will expand and strengthen the research team’s capabilities in order to accelerate the pace of development for the next generation of spider silk technologies. 

These new roles will significantly expand the current research team’s development throughput. This in turn will allow for the acceleration of numerous designs for fibrous and non-fibrous spider silk protein concepts, currently on the drawing board, to be developed into working materials and production.

“We currently have numerous new material concepts and opportunities for spider silk on the drawing board. Bringing on additional senior-level researchers should provide our team with the additional technical support and assistance needed to advance these concepts into new transgenics and materials,” said Company COO Jon Rice. “This is an exciting time for the Company and our R&D team as we look to accelerate the timing for transitioning new spider silk concepts from the lab into production.”

Highly qualified candidates are encouraged to apply via the job posting on Indeed or by clicking here

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Ann Arbor, MI – January 26, 2023– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has delivered the first two hybrid-cross Dragon Silk^TM strains to its third-party production partner in Vietnam. These strains were developed to address the most significant immediate hurdle to large-scale production, the robustness of our silkworms within the large-scale production environment. These new lines are the first of several planned silkworm strains in our hybridization program, which are explicitly designed to increase robustness and cocoon size. 

These strains blend the mechanical performance of the Company’s original Dragon Silk with the size and robustness of native production silkworm strains. The Company engineered these strains as part of its development program to bring needed increased resiliency to the large-scale production environment. 

Best practices employed by the most advanced silkworm egg production facilities include utilizing a multi-line cross-mating protocol to generate increased robustness. The result of first-generation cross-matings yield larger cocoons and more resilient silkworm offspring. As these increased performance attributes only last one generation, it is vital that central silkworm egg production operations sustain each of these separate lines in order to create successive generations of hybrid crosses. 

Kraig Labs begins its transition to multi-line cross-mating with these two new hybrids. Once established at the production facilities, the Company will start cross-matings to produce our first two-line production hybrids. Kraig Labs believes this will strengthen its production operations, increase silkworm resiliency, and significantly improve environmental tolerance.  

As part of the Company’s ongoing development efforts to commercialize spider silk production, it is also developing a four-line hybrid-cross program that should further improve yields. This program is under development at the Company’s R&D headquarters located in the USA and is planned to begin rollout in stages later this year following the successful implementation of the two-line hybrid-cross model.

“Work with our production partner in Vietnam has accelerated the identification of challenges and opportunities in scaling up production to metric tonnage levels,” said Company COO Jon Rice. “We are very pleased to announce the delivery of these new hybrid lines and we are excited about our ongoing development of the four-line hybrid-cross. The implementation of the four-line hybrid program is designed to deliver significant improvements in production capacity and yield.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “should,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Ann Arbor, MI., November 21, 2022 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has completed the debt-to-equity conversion on $8 million of convertible debentures with Yorkville Advisors. This closeout comes several months ahead of schedule and positions the Company to enter 2023 without any convertible debt obligations to Yorkville Advisors.

The Company would like to thank Yorkville Advisors and Maxim Group for supporting its vision to transform the textile markets with large-scale production of cost-effective and eco-responsible spider silk. 

Kraig Labs currently has more than $4.5 million of deployable liquid assets and will continue to use this capital to develop end-market products and strengthen the supply chain creating its revolutionary spider silk technologies. 

“While this financing has been a critical element of our transition to commercialization, we are pleased to report that we have eliminated the burden of this debt and enter the holiday season in a solid financial position. We continue to judiciously deploy this capital to build out our spider silk production capacity. Our focus now is on increasing that production, including further strengthening our production infrastructure. An important part of that program is the planned rollout of new hybrids. Our target remains metric ton production,” said CEO Kim Thompson.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Ann Arbor, Michigan., – July 18, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the signing of its first 3^rd party production contract for large scale manufacturing of the Company’s recombinant spider silk. The Company expects to immediately begin operations with this contractor producing hundreds of kilograms of spider silk per month and to achieve production levels reaching multiple metric tons of spider silk per month as early as the first quarter of 2023. The contractor is in possession of the Company’s specialized eggs and anticipates a 90-day ramp-up for the first deliveries under the contract.

Pilot testing with this contractor during the first two quarters of 2022 demonstrated the capacity and expertise of this manufacturer to operate at a large scale and with excellent quality.

Under the contract terms, Kraig Labs will become a minority owner of the silk producer. Kraig Labs will have complete access to the manufacturer’s financial records and an onsite presence to ensure the proper handling and security of the Company’s propriety spider silk technology.

“Our business model was designed to leverage the existing silk production infrastructure. The signing of this agreement rapidly expands our access into that production network and brings us to the next critical stage in our business plan,” said Company COO Jon Rice. “Working with this contract manufacturer, we will soon be ready to deliver metric tons of eco-responsible and cost-effective spider silk to the consumer markets.”

In the coming days, the Company plans to release the first in a series of behind-the-scenes videos looking into its operations in Vietnam and the commercialization of its spider silk materials.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Ann Arbor, MI – July 6, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has produced several new lines of larger hybrid Dragon Silk^TM silkworms for its production operations in Vietnam. These new breeds of silkworms were explicitly created for large-scale production. 

With a larger cocoon and longer silk filament, these optimized Dragon Silk breeds reduce production costs and increase throughput.

The new breeds were created using a process of hybridization, combining the best properties of Dragon Silk with the best practices in silkworm breeding to improve the size and robustness of the silkworm strain. Commonly used in commercial mundane silk production, the process of creating these production hybrid silkworms delivers between 30-100% larger silk cocoons than non-hybridized silkworms.

The Company first began the development of large cocoon hybrids in 2018. The success of that effort is the foundation of today’s announcement and the rollout of this technology into production. Commercializing this technology required the Company to develop multiple strains of Dragon Silk hybrids that, when paired together, deliver a consistent and scalable large cocoon production platform.

“The hybridization program was a key part of the Company’s technology roadmap and something our R&D team has been quietly working on behind the scenes,” said Company COO Jon Rice. “Today, we announce that this technology is in the factory. This technology will lower our operating costs from rearing all the way through silk reeling and spinning. Over the coming months, our production team will transition egg production to this new, larger Dragon Silk line.”

Accelerating the transition of these new larger breeds of Dragon Silk to production was driven by the Company’s success with 3^rd party contract production and our rapidly growing demand for increased quantities of Dragon Silk.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – May 17, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the first sample shipment of its recombinant spider silk fibers and fabrics for use and evaluation into a range of biomedical applications. This shipment was made in response to the significant increase in the requests for its propriety spider silk technology, over the last two quarters, for tissue engineering applications.

Aided by its unique blend of mechanical and chemical properties, spider silk has long been recognized as an ideal natural biomaterial. As a lightweight, biocompatible, and biodegradable material, spider silk applications have been tested in numerous morphologies, including; fibers, films, hydrogels, non-woven fabrics, foams, etc. While the first known cases of sutures made from spider silk date back to the 18^th century, limitations in the production and costs of spider silk have prevented its broad adoption.

Kraig Labs’ revolutionary approach, creating recombinant spider silk technology utilizing genetically enhanced silkworms, unlocks the door for large-scale adoption of spider silk for biomedical applications. This system merges the performance of spider silk with the well-established, large-scale supply chain for mundane silk.

With the growth of its production operations in Vietnam over the last two quarters, the Company is now positioned to allot a portion of its spider silk production to address the medical community’s needs. This week’s shipments are just the first in what the Company hopes will be a significant mid to long-term market growth opportunity for Kraig Labs and its foray into the growing field of bioengineering.

“Over the last month, we have seen a significant increase in the demand from the medical field for our spider silk fibers and fabrics,” said COO, Jon Rice. “With the great work our team in Vietnam has done, increasing monthly silk production, we are now positioned to begin supplying R&D samples for this new and exciting end market. As these applications often require FDA approval, we believe the biomedical space has the potential to play an important role in the Company’s long-term growth. Over the coming months, we will be closely monitoring the results of these first tests and assessing additional opportunities for the spider silk gels and films that we have already developed into the broad field of biomaterials.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – May 3, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has strengthened its second-quarter production expansion with a new vendor quality assurance program. This new program will allow the Company to screen numerous mulberry suppliers and grow its database of trusted vendors. 

This new vendor verification program was put in place to address the Company’s growing demand for high-quality mulberry as a feedstock for its expanding production of recombinant spider silk. As the primary raw input for the Company’s spider silk production, growing its supply base of verified mulberry producers is a crucial component for the continued production expansion. 

Equipment and processes refined in the first quarter have positioned the Company to focus nearly all of this quarter’s operations on finished yarn production. 85% of all silkworms produced this month are slated for spinning and use in finished fabrics and garments. These materials will be dedicated to the Company’s joint venture apparel brand, Spydasilk^TM. The remaining 15% of production will be devoted to the Company’s regenerative breeding program and growing the production base for the third quarter and beyond. 

The relationship between nutrition and high-quality silk production cannot be overstated. Nutritional management is one the most important factors in maintaining optimal colony productivity and wellbeing. This new vendor verification process will play an essential role as the Company looks to the future and outgrowing its existing production footprint and supplier base.

“Prodigy Textiles is experiencing intensive growth,” said Company COO, Jon Rice. “Putting systems in place to ensure that we are able to sustain Dragon Silk’s™ record-setting performance levels is key to managing that growth and delivering cost-effective and eco-responsible spider silk. This new supplier verification process will give us the confidence to aggressively pursue the growth needed, by increasing feed efficiency and maintaining feed quality, to fulfill material demand for months and years to come.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., Jan. 20, 2022 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the completion of an additional $3 million funding agreement with Yorkville Advisors (“Yorkville”). These additional funds, together with those from the previously announced transactions, account for an $8 million total Yorkville investment into Kraig Labs.

As a result of this successful capitalization program, the Company has elected not to renew the previously anticipated reverse stock split. The Company is focused on advancing the commercialization of spider silk. Kraig Labs will increase its capital deployment into key priorities, including commercialization, advanced research and development, and expansion at the Prodigy Textiles factory.

“This funding allows us to advance our strategic plans and transform our resources into more robust operations. We will immediately invest these capital expenditures to accelerate commercialization at Prodigy Textiles production facilities,” stated Company COO, Jon Rice.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., Jan. 18, 2022 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces it has completed production of the first Dragon Silk yarn produced entirely in Vietnam. The finished recombinant spider silk yarn was spun from raw spider silk produced at Prodigy Textiles, the Company’s subsidiary located in Quang Nam province, Vietnam.

Today’s announcement marks a significant milestone for Kraig Labs, Prodigy Textiles, and the large-scale production of recombinant spider silk. This production run of Dragon Silk exhibits Prodigy Textiles’ full integration into Vietnam’s substantial silk textile industry. Vietnam produced nearly 1,000 metric tons of mundane silk in 2020.¹   This same supply chain was used, from start to finish, to create the first Dragon Silk made entirely in Vietnam.

While Prodigy Textiles remains focused on ramping up the output of recombinant spider silk cocoons, these supporting vendors will play an essential role in processing that silk into finished goods for a wide range of consumer markets.

The Company plans to ship this Dragon Silk yarn to SpydaSilk Enterprises, in Singapore, a joint venture partially owned by the Company, for weaving into fabrics and finished garments.  

Over the coming months, Prodigy will continue to leverage this expanded silk production success to address the material needs of SpydaSilk and make additional materials available for purchase to fill the numerous and backlogged material requests it has received.

“The successful completing of this Dragon Silk yarn produced entirely utilizing the Vietnamese supply chain is a substantial achievement for the Kraig Labs and our vision for eco-responsible and cost-effective spider silk,” said COO Jon Rice. “I am extremely proud of the team at Prodigy for achieving this major milestone, while overcoming several obstacles to get this done as quickly as they did. 2022 is positioned to be a breakout year for the commercial sales of Dragon Silk and our broader recombinant spider silk technologies.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com